Extensive experience in drug discovery and biomarker research for neurodegenerative, neurodevelopmental and psychiatric indications ranging from target assessment to clinical development up to phase III. Strong experience in clinical development applying biomarker for decision making. Solid background in companion diagnostic development for neuroscience programs. Very familiar with different approaches to identify biomarkers, new drug targets and therapeutic modalities, ranging from small molecules to biopharmaceuticals. Strong leadership and organizational skills with significant experience in leading multi-cultural teams. Expert reviewer for the Horizon 2020 program of the European commission.

Biomarker Experimental Medicine Leader and Group Leader @ Accountable for the development and implementation of biomarker strategies in clinical projects up to phase III. Translation of biomarkers from preclinical to clinical applications and companion diagnostic development. From February 2011 to Present (4 years 10 months) Basel Area, SwitzerlandExpert Reviewer @ Expert Reviewer for the Horizon 2020 program of the European Commission From 2014 to 2014 (less than a year) Brussels Area, BelgiumGroup leader preclincical biomarker CNS @ Responsible for neuroscience preclinical biomarker program strategy and implementation. Project leader for PET imaging ligand identification, set up of high-throughput screen and chemical optimization program. From April 2009 to April 2011 (2 years 1 month) Basel Area, SwitzerlandSenior Research Scientist @ Primary and secondary screening assays for lead optimization and clinical candidate selection for Alzheimer’s disease programs. New target identification and validation for neurodegenerative diseases From 2001 to 2009 (8 years) Basel Area, SwitzerlandHead of Biology @ Pharmacological profiling of kinase inhibitors. Analysis of mitogen and stress activated kinase pathways relevant for neurodegeneration. From 2000 to 2001 (1 year) Munich Area, GermanySenior Scientist @ Generation and characterization of animal models for Alzheimer’s disease. Development High-Throughput-Screening tests and cell based screening assays to identify lead structures for neurodegenerative diseases From 1995 to 2000 (5 years) Paris Area, FrancePostdoctoral Fellow @ Identification of ApoE4 as risk factor for sporadic Alzheimer’s disease. Transgenic mouse models for Alzheimer’s disease. From January 1994 to January 1995 (1 year 1 month)

Doctor of Philosophy (Ph.D.), Molecular Biology @ Heidelberg University Christian Czech is skilled in: Drug Discovery, Biomarkers, Alzheimer's disease, Autism Spectrum Disorders, Research, Clinical Development, Disease, Drug Development, Translational Research, Neuroscience, In Vivo, In Vitro, Clinical Trials, Biotechnology, Molecular Biology